Therapeutic Effects of Adalimumab in Patients with Resistant Psoriasis Patients by DLQI and PASI Questionnaires

Abstract

The aim of this study was to evaluate the effect of Adalimumab in patients with refractory psoriasis. Materials and Methods: In this clinical trial study, 60 patients with psoriasis who were admitted to the dermatology clinics of Tabriz University of Medical Sciences in two groups of intervention (Adalimumab) and control were examined. The patients questionnaire consists of three parts: The first part included patients' demographic information including age, sex, marital status, duration of the disease and the type of disease. In the second part, the standardized Persian version of DLQI was used to evaluate the quality of life of patients. This questionnaire is designed for adults over 16 years old. The third part is related to the severity of the disease, which was determined based on the PASI score. Results: They were between 17 and 61 years old and the sex ratio of male to female patients was almost equal (1: 0.9). At the beginning of the study, the PASI score of the patients in the intervention group was 42.52±6.57 and at the end of the second month it was 1.73±1.37 (p=0.001). In the control group, the PASI score decreased after treatment and this decrease was statistically significant (26.84±9.29 vs. 9.72±8.23; p=0.002). The mean DLQI score in the intervention group was 23.93±7.25 at the beginning of the study and 5.90±2.79 at the end of the second month (p=0.012). The mean DLQI score in the control group at the beginning of the study was 23.53±4.62 and at the end of the second month was 14.40±5.78 (p=0.012).